These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 10625927)

  • 1. Telomerase as an anti-cancer drug target: will it fulfil its early promise?
    Newbold RF
    Anticancer Drug Des; 1999 Aug; 14(4):349-54. PubMed ID: 10625927
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overcoming the immortality of tumour cells by telomere and telomerase based cancer therapeutics--current status and future prospects.
    Kelland LR
    Eur J Cancer; 2005 May; 41(7):971-9. PubMed ID: 15862745
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Telomerase as an anti-cancer target: current status and future prospects.
    Neidle S; Kelland LR
    Anticancer Drug Des; 1999 Aug; 14(4):341-7. PubMed ID: 10625926
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological intervention strategies for affecting telomerase activity: future prospects to treat cancer and degenerative disease.
    Tárkányi I; Aradi J
    Biochimie; 2008 Jan; 90(1):156-72. PubMed ID: 17945408
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug insight: Cancer cell immortality-telomerase as a target for novel cancer gene therapies.
    Keith WN; Bilsland A; Hardie M; Evans TR
    Nat Clin Pract Oncol; 2004 Dec; 1(2):88-96. PubMed ID: 16264826
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Telomere and telomerase in human cancer].
    Hiyama K; Hiyama E; Ishioka S; Yamakido M
    Gan To Kagaku Ryoho; 1997 Jan; 24(2):196-201. PubMed ID: 9030230
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Telomerase and cancer.
    Harley CB; Kim NW
    Important Adv Oncol; 1996; ():57-67. PubMed ID: 8791128
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction of apoptosis and inhibition of telomerase activity in human bone marrow and HL-60 p53 null cells treated with anti-cancer drugs.
    Malerba I; Gribaldo L; Diodovich C; Carloni M; Meschini R; Bowe G; Collotta A
    Toxicol In Vitro; 2005 Jun; 19(4):523-32. PubMed ID: 15826810
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Telomerase antagonists GRN163 and GRN163L inhibit tumor growth and increase chemosensitivity of human hepatoma.
    Djojosubroto MW; Chin AC; Go N; Schaetzlein S; Manns MP; Gryaznov S; Harley CB; Rudolph KL
    Hepatology; 2005 Nov; 42(5):1127-36. PubMed ID: 16114043
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological telomerase inhibition can sensitize drug-resistant and drug-sensitive cells to chemotherapeutic treatment.
    Ward RJ; Autexier C
    Mol Pharmacol; 2005 Sep; 68(3):779-86. PubMed ID: 15939802
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Telomere length mediates the effects of telomerase on the cellular response to genotoxic stress.
    Rubio MA; Davalos AR; Campisi J
    Exp Cell Res; 2004 Aug; 298(1):17-27. PubMed ID: 15242758
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacodynamics of the G-quadruplex-stabilizing telomerase inhibitor 3,11-difluoro-6,8,13-trimethyl-8H-quino[4,3,2-kl]acridinium methosulfate (RHPS4) in vitro: activity in human tumor cells correlates with telomere length and can be enhanced, or antagonized, with cytotoxic agents.
    Cookson JC; Dai F; Smith V; Heald RA; Laughton CA; Stevens MF; Burger AM
    Mol Pharmacol; 2005 Dec; 68(6):1551-8. PubMed ID: 16150933
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Telomerase as an emerging target to fight cancer--opportunities and challenges for nanomedicine.
    Philippi C; Loretz B; Schaefer UF; Lehr CM
    J Control Release; 2010 Sep; 146(2):228-40. PubMed ID: 20381558
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of canine telomerase in vitro and in vivo using RNAi: further development of a natural canine model for telomerase-based cancer therapies.
    Lund JR; Paoloni M; Kurzman I; Padilla M; Argyle DJ
    Vet J; 2008 Aug; 177(2):192-7. PubMed ID: 17981480
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Telomerase as a target for cancer therapy.
    Parkinson KE
    Curr Opin Investig Drugs; 2005 Jun; 6(6):605-10. PubMed ID: 15988912
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Telomere biology of pediatric cancer.
    Tabori U; Dome JS
    Cancer Invest; 2007; 25(3):197-208. PubMed ID: 17530490
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Telomerase as a therapeutic target.
    Huminiecki L
    Acta Biochim Pol; 1996; 43(3):531-8. PubMed ID: 8922038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Telomerase inhibition and telomere targeting in hematopoietic cancer cell lines with small non-nucleosidic synthetic compounds (BIBR1532).
    El Daly H; Martens UM
    Methods Mol Biol; 2007; 405():47-60. PubMed ID: 18369817
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of a quinoxaline derivative that is a potent telomerase inhibitor leading to cellular senescence of human cancer cells.
    Kim JH; Kim JH; Lee GE; Kim SW; Chung IK
    Biochem J; 2003 Jul; 373(Pt 2):523-9. PubMed ID: 12689331
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Consequences of telomerase inhibition and combination treatments for the proliferation of cancer cells.
    Chen Z; Koeneman KS; Corey DR
    Cancer Res; 2003 Sep; 63(18):5917-25. PubMed ID: 14522918
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.